دورية أكاديمية
أعرض في EDS

The effect of hsCRP on TyG index-associated cardiovascular risk in patients with acute coronary syndrome undergoing PCI.

التفاصيل البيبلوغرافية
العنوان: The effect of hsCRP on TyG index-associated cardiovascular risk in patients with acute coronary syndrome undergoing PCI.
المؤلفون: Ma X; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. maxiaotengai@163.com., Chu H; Department of Anesthesia, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China., Sun Y; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China., Cheng Y; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China., Zhang D; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China., Zhou Y; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China., Liu X; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. liuxl9881@163.com., Wang Z; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. zjwang1975@hotmail.com.
المصدر: Scientific reports [Sci Rep] 2024 Aug 05; Vol. 14 (1), pp. 18083. Date of Electronic Publication: 2024 Aug 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Acute Coronary Syndrome*/blood , C-Reactive Protein*/metabolism , C-Reactive Protein*/analysis , Percutaneous Coronary Intervention*/adverse effects , Triglycerides*/blood, Humans ; Male ; Middle Aged ; Female ; Aged ; Retrospective Studies ; Risk Factors ; Blood Glucose/analysis ; Blood Glucose/metabolism ; Biomarkers/blood
مستخلص: The effect of systemic inflammation, represented by high-sensitivity C-reactive protein (hsCRP), on triglyceride glucose (TyG) index-associated cardiovascular risk in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) has not yet been determined. This study was a retrospective analysis of a single-center prospective registry and finally included 1701 patients (age, 60 ± 10 years; male, 76.7%). The primary endpoint was defined as major adverse cardiovascular events (MACE), including cardiovascular mortality, non-fatal stroke, and non-fatal myocardial infarction. In the multivariate COX regression model that included the GRACE risk score, higher TyG index was significantly associated with a greater incidence of MACE in patients with hsCRP levels less than 2 mg/L but not 2 mg/L or more (P for interaction = 0.039). Each unit increase in the TyG index was independently associated with a 52% increased risk of MACE only in patients with hsCRP levels less than 2 mg/L (P = 0.021). After adjustment for other confounding factors, including the GRACE risk score, compared with those in the group of TyG index < 8.62 and hsCRP < 2 mg/L, patients in the group of TyG index ≥ 8.62 and hsCRP ≥ 2 mg/L had a 3.9 times higher hazard ratio for developing MACE. The addition of both TyG index and hsCRP had an incremental effect on the predictive ability of the GRACE risk score-based prognostic model for MACE (C-statistic: increased from 0.631 to 0.661; cNRI: 0.146, P = 0.012; IDI: 0.009, P < 0.001). In conclusion, there was a significant interaction between the TyG index and hsCRP for the risk of MACE, and the TyG index was reliably and independently associated with MACE only when hsCRP levels were less than 2 mg/L. Furthermore, high TyG index and high hsCRP levels synergistically increased the risk of MACE, suggesting that the prognostic value of TyG index combined with hsCRP might be promising in patients with ACS undergoing PCI.
(© 2024. The Author(s).)
References: Coron Artery Dis. 2023 May 1;34(3):210-215. (PMID: 36762630)
Nephrol Dial Transplant. 2009 Aug;24(8):2482-8. (PMID: 19307229)
Cell Metab. 2012 May 2;15(5):635-45. (PMID: 22560216)
Diabetes. 2013 Mar;62(3):721-31. (PMID: 23069625)
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1449-1455. (PMID: 31336505)
Metabolism. 2010 Jun;59(6):824-30. (PMID: 20004425)
BMJ. 2019 Nov 5;367:l5887. (PMID: 31690574)
Endocr Rev. 2019 Dec 1;40(6):1447-1467. (PMID: 31050706)
Cardiovasc Diabetol. 2023 Jul 6;22(1):170. (PMID: 37415168)
J Pak Med Assoc. 2022 May;72(5):986-988. (PMID: 35713073)
Cardiovasc Diabetol. 2022 May 6;21(1):68. (PMID: 35524263)
JAMA. 2008 Apr 2;299(13):1561-73. (PMID: 18378631)
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S307-S309. (PMID: 28365222)
Cardiovasc Diabetol. 2020 Mar 10;19(1):31. (PMID: 32156279)
Metabolism. 2006 Feb;55(2):183-7. (PMID: 16423624)
Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3103-3110. (PMID: 34531107)
Heart. 2010 Mar;96(5):339-46. (PMID: 20197361)
Int J Cardiol. 2022 Sep 15;363:20-22. (PMID: 35716932)
J Geriatr Cardiol. 2022 Jun 28;19(6):456-468. (PMID: 35845160)
Circulation. 2002 Dec 3;106(23):2908-12. (PMID: 12460870)
PLoS Med. 2022 Feb 22;19(2):e1003911. (PMID: 35192610)
Lancet. 2005 Oct 8;366(9493):1279-89. (PMID: 16214598)
Cardiovasc Diabetol. 2022 Aug 5;21(1):145. (PMID: 35932019)
JAMA. 2006 Dec 6;296(21):2572-81. (PMID: 17101640)
Nutr Metab Cardiovasc Dis. 2023 Jun;33(6):1245-1253. (PMID: 37095018)
Diabetol Metab Syndr. 2023 Sep 2;15(1):180. (PMID: 37660067)
Eur Heart J. 2021 Jan 1;42(1):113-131. (PMID: 32176778)
Cardiovasc Diabetol. 2010 Dec 19;9:92. (PMID: 21167068)
J Clin Invest. 2006 Jul;116(7):1813-22. (PMID: 16823479)
Angiology. 2023 Feb;74(2):139-148. (PMID: 36112779)
Ann Biol Clin (Paris). 2017 Apr 1;75(2):225-229. (PMID: 28377336)
Diabetologia. 2021 May;64(5):1169-1183. (PMID: 33544171)
Circulation. 2019 Oct 15;140(16):1308-1317. (PMID: 31530008)
JAMA. 2022 Feb 15;327(7):662-675. (PMID: 35166796)
Eur Heart J. 2010 Feb;31(3):290-7. (PMID: 19578164)
Nephron. 1976;16(1):31-41. (PMID: 1244564)
Cardiovasc Diabetol. 2018 Aug 31;17(1):122. (PMID: 30170598)
N Engl J Med. 2022 Nov 24;387(21):1923-1934. (PMID: 36342113)
PLoS One. 2017 Jun 2;12(6):e0178672. (PMID: 28575103)
JAMA. 2007 Sep 12;298(10):1180-8. (PMID: 17848652)
Ann Med. 2013 May;45(3):242-53. (PMID: 22834949)
Nutrients. 2023 Jun 19;15(12):. (PMID: 37375712)
N Engl J Med. 2016 Apr 7;374(14):1321-31. (PMID: 26886418)
Cardiovasc Res. 2014 Jul 15;103(2):324-36. (PMID: 24788416)
Can J Diabetes. 2023 Jul;47(5):428-434. (PMID: 36996968)
Biomolecules. 2018 Aug 23;8(3):. (PMID: 30142970)
معلومات مُعتمدة: 82200405 Youth Program of National Natural Science Foundation of China; 2022YFC3602500 National Key Research and Development Program of China; 2022-2-1052 Capital's Funds for Health Improvement and Research
فهرسة مساهمة: Keywords: Acute coronary syndrome; High-sensitivity C-reactive protein; Major adverse cardiovascular events; Percutaneous coronary intervention; Triglyceride glucose index
المشرفين على المادة: 9007-41-4 (C-Reactive Protein)
0 (Triglycerides)
0 (Blood Glucose)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20240805 Date Completed: 20240805 Latest Revision: 20240809
رمز التحديث: 20240809
مُعرف محوري في PubMed: PMC11300796
DOI: 10.1038/s41598-024-69158-0
PMID: 39103439
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-69158-0